Healthcare Industry News: RedPath Integrated Pathology
News Release - May 19, 2009
Molecular Diagnostics Company, RedPath, Appoints Dennis M. Smith, Jr., M.D. as Chief Medical Officer
PITTSBURGH--(HSMN NewsFeed)--RedPath Integrated Pathology, Inc., a molecular diagnostics company dedicated to the effective diagnosis and treatment of cancer, today announced that it has named Dennis M. Smith, Jr., M.D. to serve as RedPath’s Chief Medical Officer effective immediately.Dr. Smith’s professional career includes serving on the executive management team and Board of Directors of AmeriPath, Inc. (NASDAQ:PATH ). While at AmeriPath, Dr. Smith’s positions included Chief Medical Officer, Executive Vice-President of Genomic Strategies, and Executive Director of AmeriPath’s Center for Advanced Diagnostics. Dr. Smith has previously held board seats at Immucor, Inc. (NASDAQ: BLUD ), the American Association of Blood Banks where he served as President, and the National Blood Foundation where he served as Chairman. In the 1980’s, Dr Smith was Executive Head and Director of Blood Services for the American Red Cross in Nashville, assistant professor of pathology at Vanderbilt, and Director of Laboratories and Chairman of the Department of Pathology at Memorial Hospital, Jacksonville, Florida, where he co-founded Memorial Laboratories, a successful outreach reference laboratory. Currently, Dr. Smith sits on the board of directors of Clarient, Inc. (NASDAQ:CLRT ), RedPath Integrated Pathology, Inc., and Jacksonville Country Day School, and the Committee of Visitors for Vanderbilt University School of Engineering.
Mark D. Myslinski, RedPath’s President and Chief Executive Officer, commented that he is thrilled to have Dr. Smith on the leadership team and looks forward to working with Dr. Smith who brings additional medical and laboratory medicine acumen to RedPath Integrated Pathology. “Dr. Smith and I share a vision which is to improve the lives of people with cancer by applying novel diagnostic tools to solve clinical patient management dilemmas.”
About RedPath Integrated Pathology Inc.
RedPath Integrated Pathology, Inc. is a genomics-based molecular diagnostics company that provides complex cancer diagnostic testing for pathologists, oncologists and clinicians. RedPath’s patented molecular-based analysis, PathFinderTG(R), integrates with routine pathology review of fixed slides, cytology and fluid specimens to render an earlier and more definitive diagnosis, improving patient outcomes and reducing healthcare costs. For more information about RedPath, please visit www.redpathip.com.
Source: RedPath Integrated Pathology
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
